| Year |
Citation |
Score |
| 2016 |
Chao MP, McKenna KM, Cha A, Feng D, Liu J, Sikic BI, Majeti R, Weissman IL, Takimoto C, Volkmer J. Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr13 |
0.754 |
|
| 2015 |
McCracken MN, Cha AC, Weissman IL. Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3597-601. PMID 26116271 DOI: 10.1158/1078-0432.Ccr-14-2520 |
0.746 |
|
| 2012 |
Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, ... ... Cha AC, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7. PMID 22451913 DOI: 10.1073/Pnas.1121623109 |
0.501 |
|
| 2011 |
Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America. 108: 5009-14. PMID 21383193 DOI: 10.1073/Pnas.1100551108 |
0.623 |
|
| 2010 |
Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142: 699-713. PMID 20813259 DOI: 10.1016/J.Cell.2010.07.044 |
0.703 |
|
| Show low-probability matches. |